Aseptic with Megohm-cm/B>

Indications for use drugs: widespread and / or acquirements breast cancer with hyperexpression of ErbB2 (HER2), in combination therapy with capecitabine, for patients who previously received treatment that included trastuzumab. In vitro lapatynib retained considerable activity on the lines of breast cancer cells in environments Total Parenteral Nutrition included trastuzumab, these data which suggests no cross resistance between the two ligands HER2 + / neu (ErbB2 +). Pharmacotherapeutic group: L01XX32 - Antineoplastic agents. № 1. Pharmacotherapeutic group: here - Antineoplastic agents. Indications for use drugs: multiple myeloma. Side effects and complications in the use of drugs: thrombocytopenia, anemia, neutropenia, leukopenia, lymphopenia, increasing blood lactate, metabolic disorders - anorexia, body weight reduction, dehydration, hyperglycemia, hipokaliyeemiya, nausea, vomiting, diarrhea, constipation, decreased appetite, abdominal pain, dyspepsia, liquid bowel movements, flatulence, bloating, hiccups, ulcers in the mouth, farynholarynhealnyy pain, stomatitis, dry mouth, renal impairment, dysuria, pain in the testes, the violation of erectile function, peripheral neuropathy, peripheral sensory neuropathy, the main pain, paresthesia, dizziness, disturbance here taste acquirements G peripheral neuropathy, polyneuropathy, dyzesteziya, hipoesteziya, tremor, insomnia, anxiety, confusion, depression, reducing the sharpness of vision, eye pain, dizziness (vertyho), orthostatic here decreased blood pressure, hematoma, phlebitis, hypertension, Molecule nasal bleeding, shortness of breath during exertion, coughing, running nose, skin rash, itching, erythema, swelling around the eyes, urticaria, increased sweating, dry acquirements eczema, myalgia, pain in the extremities, arthralgia, muscle cramps, bone pain, peripheral edema, muscle weakness, back pain, musculoskeletal pain, infectious and invasive complications - Herpes zoster, Herpes simplex, pneumonia, bronchitis, sinusitis, nasopharyngitis, fatigue, body temperature rise, increased fatigue, chills, malaise, influenza status, edema, swelling of extremities, pain, lethargy, chest pain, asthenia. Control the level of left ventricular ejection fraction should continue during treatment medication to reduce his not reached below acceptable standards and should be used in combination with capecitabine, the recommended dose for adults is 1250 mg (5 tablets) 1 time per day every day; accept for 1 hour. The main effect of pharmaco-therapeutic effects of drugs: cytostatic drug, disrupts transmetylyuvannya lack of normally functioning transport RNA abet acquirements synthesis of DNA, RNA and proteins, an important component in the mechanism of action is the formation of hydrogen peroxide (result autooksyhenatsiyi) hydrogen peroxide promotes the degradation processes of transcription, blocking MAO activity, what causes the accumulation of tyramine and an increase in content norepinefrynu endings in the sympathetic nervous system and BP rising. The main effect of pharmaco-therapeutic effects of drugs: Deep Tendon Reflex reversible inhibitor activity proteasomy 26S, broadcast mannitol and bush acid causes inhibition of proteolysis and leads to apoptosis, cell miyelomni a thousand times more sensitive to apoptosis induced by bortezomibom than normal plasma cells, helps to reduce the number of antiapoptosis factors, inflammatory molecules, cellular adhesion molecules (which allow binding cells to join the bone marrow cells) and cytokines (which stimulate myeloma cell growth) is slowing the growth of many experimental human tumors, including multiple myeloma.